Looking for our Business Solutions? Click here:CloudQuote APIsContact Us
Stocks in the NewsMost Active StocksPercent GainersPercent LosersFollowed Stocks
,

Latest News

Should You Forget SpaceX Stock?fool.com
Space Exploration Technologies needs a lot to go right to justify its valuation.
Via The Motley Fool · November 21, 2026
Zebra Technologies Sees 2027 Growth as Delivery Refreshes Offset Memory Cost Pressuresmarketbeat.com
Zebra Technologies (NASDAQ:ZBRA) expects strong demand and large delivery-device refreshes to support sales growth in 2027, while higher memory costs are prompting the company to raise prices and build inventory, Chief Financial Officer Nathan Winters said at a Stephens investor conference in Nashvi
Via MarketBeat · November 21, 2026
Split $3,000 Across These 3 Value Stocks and Ignore Them Until 2031fool.com
All three of these value stocks have growth catalysts.
Via The Motley Fool · November 21, 2026
After Its Worst Week in 18 Years, Nvidia Now Faces an SEC Investigation. What It Means for Investorsfool.com
On top of its other woes, Nvidia now faces an SEC investigation.
Via The Motley Fool · November 21, 2026
DoorDash CEO Says AI Spending Jumped 20-Fold, With More Growth Aheadmarketbeat.com
DoorDash (NASDAQ:DASH) CEO Tony Xu said the company’s artificial intelligence spending rose 20-fold this year before leveling off, but he expects it to grow again as the delivery platform develops more sophisticated tools for customers. Speaking at an investor conference, Xu also discussed DoorDash
Via MarketBeat · November 21, 2026
Follow the Smart Money: 4 AI Stocks Billionaire Dan Loeb Just Boughtfool.com
Hedge fund manager Dan Loeb was buying shares of Nvidia, Space Exploration Technologies, Microsoft, and Meta Platforms in Q3 2026.
Via The Motley Fool · November 21, 2026
Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP Trialmarketbeat.com
Recursion Pharmaceuticals (NASDAQ:RXRX) has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial adenomatous polyposis, or FAP, CEO Najat Khan said at the Jefferies Healthcare Conference in London. The co
Via MarketBeat · November 21, 2026
If the Nasdaq's Correction Turns Into a Bear Market, This Is the First Stock I'll Buyfool.com
Another 7.5% fall would send the index into a bear market. Which battered giant would I buy first?
Via The Motley Fool · November 20, 2026
Incyte Bets on Drug Pipeline and Deals for Growth After Jakafi Exclusivity Endsmarketbeat.com
Incyte (NASDAQ:INCY) is counting on a pipeline of cancer and immunology treatments, along with potential acquisitions, to support growth after JAKAFI loses exclusivity, executives said at the Jefferies Global Healthcare Conference in London. President and CEO Bill Meury said the company’s core busi
Via MarketBeat · November 20, 2026
The S&P 500 Just Entered Correction Territory. Here's What It Means for Investors Right Now.fool.com
After plunging 8.6% for the week, the S&P 500 is now in a correction.
Via The Motley Fool · November 20, 2026
Crowd Pleaser….Crowdstrike Wants to Buy Zscalerfool.com
Here’s why this could be a game changer for cybersecurity investors.
Via The Motley Fool · November 20, 2026
Incyte Maps Post-JAKAFI Growth as Key Drug Data and 2027 Launch Loommarketbeat.com
Incyte (NASDAQ:INCY) is counting on growth from its existing medicines and a pipeline of late-stage treatments to support the company after JAKAFI loses exclusivity at the end of 2028, executives said at the UBS Global Biopharma Conference in London. President and Global Head of Research and Develo
Via MarketBeat · November 20, 2026
Amazon's re:Invent Conference Starts Nov. 30. Here's What the Stock Did in the Month After the Last 10.fool.com
The cloud giant's biggest week of the year is nearly here. Has the stock usually climbed after it?
Via The Motley Fool · November 20, 2026
Chipotle Mexican Grill vs. Hershey: Which Consumer Stock Is a Better Buy for 2027?fool.com
Hershey trades at a lower forward P/E than Chipotle, but the gap raises a bigger question about which stock is the better buy.
Via The Motley Fool · November 20, 2026
Here's Why Nvidia Stock Crashed on Fridayfool.com
Reports of a new investigation drove many investors to sell.
Via The Motley Fool · November 20, 2026
A TFSA Loss Doesn’t Create New Room: Here’s the Rebuilding Plan I’d Usefool.ca
A falling investment won’t create TFSA contribution room. I’d rebuild using the room I actually have and a portfolio that doesn’t need one big win.
Via The Motley Fool · November 20, 2026
A 7.9% Dividend Stock for Monthly Retirement Incomefool.ca
This Canadian REIT trades at a 38.8% discount to a key valuation measure, and offers a 7.9% yield, paid monthly, to retirees seeking passive income. Here's why it's investable...
Via The Motley Fool · November 20, 2026
Synchrony Financial Puts Lending Discipline First, Sees Walmart as Growth Opportunitymarketbeat.com
Synchrony Financial (NYSE:SYF) is prioritizing lending discipline over faster loan growth as it navigates consumer affordability pressures, Chief Financial Officer Brian Wenzel said at TD’s Financials & Fintech Conference. Wenzel said the company aims to maintain a loss rate of 5.5% to 6% and d
Via MarketBeat · November 20, 2026
Report: Goldman Sachs Predicts the S&P 500 Will Gain 26% in 12 Monthsfool.com
Despite a rocky few weeks on Wall Street, the next 12 months are looking much more bullish, according to Goldman Sachs.
Via The Motley Fool · November 20, 2026
The S&P 500 Has More Than Tripled in 10 Years, Even After Its Latest Pullback. Here’s What $1,000 in VOO Could Have Become.fool.com
A host of concerns are creating the perfect storm right now, harming market sentiment.
Via The Motley Fool · November 20, 2026
Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?fool.com
The good news is that Bristol Myers Squibb's new drugs are growing; the bad news is that one old drug is nearing its patent expiration.
Via The Motley Fool · November 20, 2026
Here's How Much Nvidia Stock Is Worth Without Jensen Huang, According to Dan Ivesfool.com
Dan Ives revised his price target on Nvidia stock following Jensen Huang's resignation as CEO.
Via The Motley Fool · November 20, 2026
Campbell's Plans $500 Million in Savings as Sales and Profit Slidemarketbeat.com
Campbell's (NASDAQ:CPB) shareholders elected all 12 director nominees and approved the company’s executive compensation and long-term incentive plan proposals at its 2026 annual meeting, according to preliminary voting results. A shareholder proposal seeking more reporting on the company’s regenerat
Via MarketBeat · November 20, 2026
Prediction: Nvidia Stock Will Do This in the 6 Months After a New CEO Takes Over, According to Historyfool.com
Nvidia is searching for a new CEO following Jensen Huang's abrupt resignation.
Via The Motley Fool · November 20, 2026
Building a $1,000-a-Month Dividend Income Stream: What It Actually Takesfool.ca
Wondering what it takes to earn $1,000/month in dividends? Here's some different scenarios and stocks that can help get you there.
Via The Motley Fool · November 20, 2026